THE US Food and Drug
Administration has approved
Probuphine, the first buprenorphine
implant for the maintenance
treatment of opioid dependence.
The product is designed to
provide a constant, low-level dose
of buprenorphine for six months
in patients who are already stable
on low-to-moderate doses of other
forms of buprenorphine, as part of
a complete treatment program.
The FDA said expanding the use
and availability of medication assisted
treatment options is
an important component of the
regulatory body’s opioid action plan
and one of three top priorities for
the U.S. Department of Health and
Human Services’ Opioid Initiative
aimed at reducing prescription
opioid and heroin related overdose,
death and dependence.The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 16
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.